1 citations
,
May 2023 in “Journal of the American Academy of Dermatology” Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.
January 2025 in “The Journal of Dermatology” Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
22 citations
,
January 1992 in “PubMed” Higher CSF 5-HIAA levels may predict better response to serotonin re-uptake inhibitors in trichotillomania.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
2 citations
,
July 2025 in “RMD Open” IL-1 blockade is effective for treating SURF, and personalized treatment is needed.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
9 citations
,
January 2022 in “Reproductive Biology and Endocrinology” High levels of male hormones and irregular periods best predict how well PCOS patients will respond to metformin treatment.
January 2026 in “Open Science Framework” This scoping review systematically maps the use of AI and ML in alopecia research, highlighting the evolution from diagnostic tools to more advanced prognostic frameworks. It identifies the dominance of CNNs for image-based diagnosis, limited multimodal integration, and a lack of prognostic or causal modeling. Key gaps include the need for generative prognosis frameworks, fairness evaluations, privacy-aware systems, and treatment-response prediction. The review provides a taxonomy of AI approaches, visual aids, and recommendations for future research, emphasizing the development of equitable AI tools for personalized prognosis and treatment planning in alopecia care.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” Methylprednisolone treatment helps most alopecia areata patients, but young age, extensive hair loss, and low vitamin D can affect results.
Higher sulfotransferase enzyme levels predict better response to minoxidil for hair growth.
April 2026 in “Meditsinskiy sovet = Medical Council” A 52-week prospective cohort study with 45 alopecia areata patients compared the efficacy of tofacitinib and baricitinib. Both drugs showed similar efficacy and safety, with median hair regrowth of 81.4% for tofacitinib and 100% for baricitinib. The study found no significant difference in achieving SALT30 or SALT ≤20% between the two treatments. However, baricitinib had a higher rate of early responders by week 12. Baseline disease severity was the only independent predictor of treatment response, emphasizing its importance in therapy planning. No serious adverse events were reported.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
January 2024 in “Authorea (Authorea)” STK11 gene polymorphism does not predict metformin response in PCOS.
January 2026 in “International Journal of Women s Health” A new model helps predict treatment success in girls with early puberty.
27 citations
,
November 2013 in “Dermatologic Therapy” New test predicts if hair loss treatment will work.
January 2020 in “Hair transplant forum international” Oral minoxidil helps female hair loss, topical finasteride treats AGA, and sulfotransferase activity predicts minoxidil effectiveness.
5 citations
,
April 2022 in “Evidence-based Complementary and Alternative Medicine” Shaoyao Gancao decoction may treat alopecia areata by affecting the PI3K/AKT signaling pathway.
7 citations
,
July 2024 in “Dermatology Practical & Conceptual” SII is a useful and affordable tool to assess and monitor alopecia areata.
November 2020 in “Postepy Dermatologii I Alergologii” Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
11 citations
,
April 2014 in “Journal of Clinical Virology” Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.
2 citations
,
May 2025 in “Diagnostics” ATR-FTIR spectroscopy could help monitor alopecia areata treatment response non-invasively.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
4 citations
,
December 2019 in “Dermatologic Therapy” Hair enzyme activity predicts minoxidil success in Brazilian women with hair loss.
January 2024 in “Research Square (Research Square)” Traditional Chinese medicine may help treat ischemic stroke by targeting specific genes and pathways.
9 citations
,
August 2019 in “Journal of The European Academy of Dermatology and Venereology” Minoxidil activation by hair enzymes predicts treatment success for female hair loss.
A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.